Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Study an important step for dog cancer therapy
dog lying down
Researchers investigated
the activation of genetic regulatory mechanisms in canine cell lines.
Researchers find similarities between human and canine cells

Scientists at the University of Veterinary Medicine, Vienna, are investigating molecular processes for targeted dog cancer therapy.

Modern cancer treatment has been revolutionised by the introduction of so-called 'targeted drugs'. However, the basis for applying these drugs in cancer therapy requires a deep understanding of the molecular mechanisms of the disease.

Now researchers have investigated an important process in the molecular genetics of cancer development in canine cells and found both similarities and differences, compared to those in humans.

In the study, the researchers investigated the activation of genetic regulatory mechanisms in canine cell lines. These cell lines have long been used by researchers to analyse pathological processes and were analysed for changes in the expression of several RNA-species.

So far, research on epithelial-mesenchyman transition (EMT) has focussed on cells of humans and mice, showing how certain pathways cooperate to allow cancer cells metastases.  Metastases form when the sedentary cancer cells gain certain properties. This allows them to move into another organ and form a new tumour.

Speaking to science news website phys.org, Mathias Muller, head of the institute for animal breeding and genetics, said:  "In the majority of cases it is the metastases that cost the patient's lives, as the original tumour can often be well controlled by radiation and surgery.

"We are interested in what is going on at the molecular level during metastasis, as it is likely that we can use this knowledge for the successful treatment of metastases."

It is well recognised that the transforming growth factor beta (TGF-beta) pathway plays a critical roll in metastasis.  Lead author Sabine Macho-Maschler expressed her satisfaction with the many similarities seen in the comparative analysis of results for canine, human and mouse cells.

"TGF-beta, for example, also plays an important role in dogs, but there are also interesting variations," she said. Her study is filled with  lists of RNAs that are regulated during EMT

The researchers say that the findings serve as a basis for further analysis. However, they are skeptical as to whether their research can improve the treatment of dogs with cancer in the near future.  

"Our newly published results are like a catalogue, perhaps an important requirement for new approaches and ideas. Ultimately, we do not even know whether many of the new drugs actually act in canine cells," said Sabine.

Become a member or log in to add this story to your CPD history

Strangles survey seeks views of horse owners

News Story 1
 With Strangles Awareness Week just around the corner (5-11 May), vets are being encouraged to share a survey about the disease with their horse-owning clients.

The survey, which has been designed by Dechra, aims to raise awareness of Strangles and promote best practices to prevent its transmission. It includes questions about horse owners' experiences of strangles, together with preventative measures and vaccination.

Respondents to the survey will be entered into a prize draw to win two VIP tickets to Your Horse Live 2025. To access the survey, click here 

Click here for more...
News Shorts
Vivienne Mackinnon elected BVA Scottish Branch President

The British Veterinary Association (BVA) has elected Vivienne Mackinnon as its new BVA Scottish Branch president.

Dr Mackinnon has over 30 years of experience in veterinary care, encompassing both small animal and mixed practice. She has worked in practices in Scotland, England, New Zealand and Australia, before joining APHA to work in frontline disease control.

In her speech, Dr Mackinnon reflected on the changes in Scotland's veterinary industry and highlighted her commitment to veterinary education.

Dr Mackinnon said: "I look forward to working with colleagues across the veterinary professions to improve animal health and welfare in the country and support veterinary workplaces."